KBI Biopharma Executive and Leadership Team

Katherine Wolf, the Chief Financial Officer at KBI Biopharma, directs all fiscal planning and capital allocation strategies to support the organization's global manufacturing footprint. Overseeing financial reporting, budgeting, and long-term investment analysis, the Chief Financial Officer ensures the company maintains the necessary liquidity to fund advanced analytical and formulation development technologies. Katherine Wolf manages the intersection of corporate growth and fiscal discipline, providing the board with critical insights regarding market expansion and operational efficiency. By optimizing the capital structure, the Chief Financial Officer enables the firm to scale production capabilities for complex biologics effectively. This leadership role involves constant collaboration with other C-suite members to align financial resources with the overarching mission of accelerating innovative medicines. Through rigorous oversight of financial performance, the Chief Financial Officer secures the stability required for sustained investment in life sciences infrastructure across international markets.

Peter Carbone, the Chief Operating Officer at KBI Biopharma, manages the end-to-end execution of cell line development and commercial manufacturing processes. Overseeing the technical operations across global facilities, the Chief Operating Officer ensures that every production cycle meets stringent quality standards for complex biologics. Peter Carbone drives the integration of specialized technologies into the manufacturing workflow, directly impacting the speed at which life sciences companies bring vaccines to market. By streamlining supply chain logistics and facility throughput, the Chief Operating Officer maximizes operational efficiency and capacity utilization. This leadership role requires constant coordination with analytical development teams to maintain seamless transitions from clinical to commercial production. Through the implementation of advanced manufacturing protocols, the Chief Operating Officer maintains the company's competitive edge in the global biopharma landscape, ensuring that all operational outputs align with the highest industry benchmarks for safety and reliability.

Toshihiro Ogawa, the President, Kbi Biopharma (Japan) at KBI Biopharma, directs all strategic initiatives and market development efforts within the Asian region. Overseeing the expansion of the company's footprint in Japan, the President, Kbi Biopharma (Japan) ensures that local life sciences partners gain full access to the firm's integrated development and manufacturing services. Toshihiro Ogawa manages the alignment of regional operations with the global corporate strategy, facilitating the delivery of complex biologics to the Japanese market. By building strong relationships with local regulatory bodies and industry stakeholders, the President, Kbi Biopharma (Japan) accelerates the adoption of the company's specialized technologies. This leadership role involves navigating unique market nuances to ensure that the organization remains a preferred partner for regional vaccine and medicine development. Through the execution of targeted growth strategies, the President, Kbi Biopharma (Japan) significantly increases the company's influence and operational reach within the competitive international biopharma landscape.

Debra Bruneau, the Chief People Officer at KBI Biopharma, architects the human capital strategy necessary to attract and retain top-tier scientific talent. Overseeing organizational development, talent acquisition, and employee engagement, the Chief People Officer ensures the workforce possesses the specialized expertise required for complex biologics production. Debra Bruneau drives initiatives that foster a culture of innovation and scientific excellence, directly supporting the company's mission to accelerate medicine development. By aligning human resources with the broader business objectives, the Chief People Officer facilitates cross-functional collaboration between research, development, and manufacturing teams. This leadership role involves designing comprehensive training programs that keep the staff at the forefront of biopharmaceutical advancements. Through the cultivation of a high-performance environment, the Chief People Officer strengthens the organizational foundation, ensuring that the company maintains the intellectual capital needed to solve the most challenging problems in the life sciences sector.